Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Molecular PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- PharmVar and the Landscape of Pharmacogenetic Resources.Clin Pharmacol Ther. 2020; 107: 43-46
- Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).Genet Med. 2017; 19: 215-223
- Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.J Clin Invest. 2012; 122: 519-528
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Clin Pharmacol Ther. 2022; https://doi.org/10.1002/cpt.2557
- The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.Drug Metab Dispos. 2014; 42: 561-565
- Complex multifactorial nature of significant hyperbilirubinemia in neonates.Pediatrics. 2009; 124: e868-e877
- Biomarkers for In Vivo Assessment of Transporter Function.Pharmacol Rev. 2018; 70: 246-277
- Urinary markers of adrenarche: reference values in healthy subjects, aged 3-18 years.J Clin Endocrinol Metab. 2005; 90: 2015-2021
- Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants.Eur J Pharm Sci. 2018; 124: 217-227
- Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.Clin Pharmacol Ther. 2016; 100: 362-370
- Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver.Clin Transl Sci. 2020; 13: 509-519
- Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.J Pharmacol Exp Ther. 2016; 357: 382-393
- Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.J Pharmacol Exp Ther. 2016; 358: 397-404
- Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.Clin Pharmacol Ther. 2018; 104: 564-574
- Coproporphyrin I and 3 excretion in bile and urine.J Clin Invest. 1972; 51: 2895-2899
- Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1∗5, SLCO1B1∗15 and SLCO1B1∗15+C1007G, by using transient expression systems of HeLa and HEK293 cells.Pharmacogenet Genomics. 2005; 15: 513-522
- Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.Drug Metab Dispos. 2020; 48: 1192-1198
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).Pharmacogenetics. 2004; 14: 429-440
- Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia.Clin Pharmacol Ther. 2019; 105: 1501-1512
- Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.J Clin Pharmacol. 2018; https://doi.org/10.1002/jcph.1080
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.Pharmacogenet Genomics. 2006; 16: 873-879
- Impact of SLCO1B1 genetic variation on rosuvastatin systemic exposure in pediatric hypercholesterolemia.Clin Transl Sci. 2020; https://doi.org/10.1111/cts.12749
- Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.Clin Pharmacol Ther. 2007; 82: 726-733
- Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.Clin Transl Sci. 2019; 12: 388-399
- Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.Drug Metab Pharmacokinet. 2019; 34: 78-86
- Effect of SLCO1B1 Genotype on Endogenous Biomarker Coproporhyrin I Baseline in Children and Adolescents.Clin Phamacol Ther. 2020; 107: S106-S107
- Utility of Coproprophyrin I to Predict Statin Exposure in Children and Adolescents.Clin Pharmacol Ther. 2021; 2021: 109https://doi.org/10.1002/cpt.2167
- Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers.Clin Pharmacol Ther. 2021; 109: 646-657
- Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans.Clin Pharmacol Ther. 2021; 110: 1622-1632
- Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.Clin Pharmacol Ther. 2016; 100: 524-536
- Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation.Molecules. 2021; 26https://doi.org/10.3390/molecules26185500
- Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.Clin Pharmacol Ther. 2017; 101: 646-656
- Considerations for Implementing Precision Therapeutics for Children.Clin Transl Sci. 2019; 12: 140-150
- Pediatric Statin Administration: Navigating a Frontier with Limited Data.J Pediatr Pharmacol Ther. 2016; 21: 380-403
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet. 2005; 366: 1267-1278
- Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.QJM. 2011; 104: 109-124
- Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis.CMAJ. 2011; 183: E1189-E1202
- Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects.Pediatr Cardiol. 2009; 30: 482-489
- The SLCO1B1∗5 genetic variant is associated with statin-induced side effects.J Am Coll Cardiol. 2009; 54: 1609-1616
- SLCO1B1 variants and statin-induced myopathy--a genomewide study.N Engl J Med. 2008; 359: 789-799
- Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.Clin Pharmacol Ther. 2011; 89: 210-216
- Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.Eur J Pharmacol. 2009; 613: 119-127
- Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.Drug Metab Dispos. 2011; 39: 1954-1960
- Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.J Pharmacol Exp Ther. 2014; 348: 452-458
- Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.Liver Int. 2017; 37: 1074-1081
- Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies.Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13112837
- Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.J Clin Oncol. 2009; 27: 5972-5978
- Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.Pediatr Blood Cancer. 2021; 68: e28858
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.Genome Res. 2012; 22: 1-8
- SLCO1B1 ∗15 allele is associated with methotrexate-induced nausea in pediatric patients with inflammatory bowel disease.Clin Transl Sci. 2022; 15: 63-69
- Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis.Pediatr Rheumatol Online J. 2021; 19: 51
- SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis.Scand J Rheumatol. 2021; 50: 213-217
- Association of SLCO1B1 ∗14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients.ACR Open Rheumatol. 2019; 1: 58-62
- Polymorphism in Organic Anion-Transporting Polypeptide Gene Related to Methotrexate Response in Rheumatoid Arthritis Treatment.J Nippon Med Sch. 2019; 86: 149-158
- Role of tyrosine kinase inhibitors in cancer therapy.J Pharmacol Exp Ther. 2005; 315: 971-979
- Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.Xenobiotica. 2018; 48: 73-78
- Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.Cancer Chemother Pharmacol. 2021; 88: 941-952
- Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.Cancer Chemother Pharmacol. 2022; 89: 383-392
- Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.J Pharm Sci. 2017; 106: 2123-2135
- Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes.Eur J Pharm Sci. 2021; 165: 105951
- Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib.Pediatr Blood Cancer. 2019; 66: e27618
- Pazopanib and Statin-Induced Rhabdomyolysis.Case Rep Oncol. 2017; 10: 954-957
- A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.Mol Cancer Ther. 2015; 14: 461-469
- Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.Eur J Cancer. 2012; 48: 465-474
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. (Accessed April 20, 2022).
- Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1.Xenobiotica. 2018; 48: 1059-1071
- Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Br J Cancer. 2014; 110: 894-898
- OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.J Clin Invest. 2018; 128: 816-825
- Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation.Clin Cancer Res. 2021; 27: 4301-4310
- Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.Drug Metabol Drug Interact. 2014; 29: 249-259
- Cholesterol Screening and Treatment Practices and Preferences: A Survey of United States Pediatricians.J Pediatr. 2017; 185: 99-105 e2
- Implementation of lipid screening guidelines in children by primary pediatric providers.J Pediatr. 2014; 164: 572-576
- Will obesity increase the proportion of children and adolescents recommended for a statin?.Circulation. 2013; 128: 2162-2165
- Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.Xenobiotica. 2016; 46: 457-466
- Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.Clin Pharmacol Ther. 2020; 107: 1004-1013
- Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.Clin Cancer Res. 2013; 19: 1458-1466
- A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.J Biol Chem. 1999; 274: 37161-37168
- Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.J Pharmacol Exp Ther. 2001; 297: 861-867
- Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.Gastroenterology. 2006; 130: 1793-1806
- Influence of OATP1B1 Function on the Disposition of Sorafenib-beta-D-Glucuronide.Clin Transl Sci. 2017; 10: 271-279
Article info
Publication history
Published online: September 28, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
